Global Hemophilia A Treatment Market Size Will Reach USD 8 Billion By 2016: Polaris Market Research

Hemophilia A patients have begun to shift from short acting to EHL factors and from on demand therapies to prophylactics. The increasing prevalent population of Hemophilia A and the rise in demand of the prophylactics treatments in developed markets will have a great impact on this market.

According to the US Centers for Disease Control and Prevention, hemophilia A occurs in 1 in 5,000 live male births. Hemophilia A is about four times as common as hemophilia B.  The number of people with hemophilia in the United States is estimated to be about 20,000 individuals. Approximately 75% of people with hemophilia around the world still receive inadequate treatment or have no access to treatment.

As of January 2018, there are over 450 reported Clinical Trials for Hemophilia A with 50+ trials currently actively ongoing. Out of all the trials, 120+ studies are funded by the pharmaceutical companies alone. The major players with drugs in Phase III are Alnylam Pharmaceuticals, Sanofi (Genzyme), BioMarin Pharmaceutical, Hoffmann-La Roche, Sinocelltech Ltd., Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Octapharma, LFB USA, Inc., Novo Nordisk A/S, Pfizer and others.

Polaris Market Research expects that with the expected launch of the promising treatments, the market is expected to expand in Hemophilia A segment. The United States dominates the Hemophilia A treatment market followed by Europe 5 and Japan. The prophylaxis segments are predicted to be the fastest growing segment whereas the on-demand therapy segment is expected to contribute close to ~50% to the market during the forecast period. With the increase in the R&D investments and rising drug innovations in this field, the market is expected to significantly expand in the next five years.

See also  Orthobiologics Market is Projected to Expand Rapidly with CAGR at 5.2% and Reach a Value of USD 11.77 Billion By 2030

RNA based therapeutics and curative gene therapies are rapidly progressing through clinical development and are seen as an attractive segment of this market.

Polaris Market Research has provided the forecasts of the Global Hemophilia A Market from 2016-2022. The major segments which has been investigated in the global market from 2016-2022 are:

  • Market Analysis by Hemophilia A treatment
  • Market Analysis by Treatments/Marketed Drugs
  • Market Analysis by G7 countries

The Marketed Therapies undertaken in forecast from 2016-2022 are:

  • Afstyla Sales Forecast
  • Eloctate Sales Forecast
  • Hemlibra Sales Forecast
  • Kogenate FS Sales Forecast
  • Kovaltry Sales Forecast
  • Nuwiq Sales Forecast
  • Obizur Sales Forecast

Get Special Discount @

The Major Indications in Hemophilia A Therapy area:

  • Prophylaxis-Market Forecast
  • On-demand therapy-Market Forecast
  • Inhibitor therapy- Market Forecast

The Market Forecast of Hemophilia A Treatment by G7 Countries

  • United States- Market Forecast
  • Germany- Market Forecast
  • France-Market Forecast
  • Italy- Market Forecast
  • Spain- Market Forecast
  • United Kingdom- Market Forecast
  • Japan- Market Forecast

Leading Companies investigated in the Report are

  • CSL Behring
  • Shire
  • Bayer
  • Biogen
  • Genentech
  • Bioverativ
  • Alnylam Pharmaceuticals
  • Sanofi (Genzyme)
  • BioMarin Pharmaceutical
  • Hoffmann-La Roche
  • Sinocelltech Ltd.
  • Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
  • Octapharma
  • LFB USA, Inc.
  • Novo Nordisk A/S
  • Pfizer

Need More Information? Inquire More About This Report Before Purchase @

What Does the Report Include?

  • Status of the Hemophilia A Treatment Market in world view.
  • Top companies operating in the market.
  • Import-Export policies regarding the products/services in the Hemophilia A Treatment Market.
  • Research and development activities.
  • Major research agenda in industry segments.
  • Segmentation according to application, type, and geography.
  • Comparative study of the domestic and international prices of the products and services and related price fluctuations.
  • Worldwide Hemophilia A Treatment Market’s driving forces and roadblocks
See also  At 11.1% CAGR, Intelligent Traffic Management System Market to Outstrip $19.8 Billion During (2022–2030) | Polaris Market Research

Impact of COVID-19 on this Market:

The pandemic of COVID-19 continues to expand and impact over 175 countries and territories across the globe. Although the outbreak appears to have slowed down, the impact of COVID-19 has already been witnessed by all the regions globally. The pandemic could influence the key aspects of the global economy such as production and supply chain along with financial markets.

We, at Polaris Market Research, better understand the impact of economic and other factors on various sectors and markets. Using our advanced research methodology, we are determined to aid your business sustain, stabilizing, and growing during the COVID-19 pandemic. With deep expertise across various industries-no matter how large or small- and with a team of highly experienced and dedicated analysts Polaris Market Research will provide you key insights about coronavirus outbreaks across different industries to guide you prepare for the future.

About Polaris Market Research

Polaris Market Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Polaris Market Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We at Polaris are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

Contact Us:

Polaris Market Research

Phone: +1-929-297-9727